July 8, 2026
TP53 mutations occur in over 50% of patients with EGFR-mutant lung cancer, representing a consistently negative prognostic factor. Dr. Rotow explains that TP53 mutations appear prominently on NGS reports, requiring clinicians to determine appropriate management strategies.
Related Posts
Optimizing Treatment Selection in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
Shared Decision-Making and Risk Stratification in EGFR-Mutant NSCLC
Comparing Intensification Strategies and Toxicity Profiles
